Webinar Description
While
biologics are considered the fastest growing segment of the pharmaceutical industry,
biosimilars are expected to grow
on faster scale. However, the process of introducing a biosimilar to an innovator product is highly complex both globally and regionally. This webinar outlines the realities and challenges to the successful market access of
biosimilars especially in the MENA region.
Learning Objective
- What are biologics?
- How does biosimilars differ from generics?
- Who are the key market players and in which therapeutic areas?
- What are the key drivers and barriers to biosimilars market access?
- The diversity of the MENA region and how does it reflect on market access?
Session 1 - "Introduction and Overview" will cover:
- Biologic products definition
- The manufacturing process
- Impact of manufacturing changes
- Importance of quality systems
- Biopharmaceutical sales by therapeutic areas
- Leading biopharmaceutical companies
Session 2 - "MENA Market Access" will cover:
- Factors affecting market access for biosimilars
- Market drivers and restraints influencing biosimilars approval, use and uptake in the MENA
- Payer differences and the implications for pricing and reimbursement
- Differences in data protection standards
Who should attend?
Medical managers, product managers, sales managers, business development managers, Regulatory Affairs and manufacturing quality personnel
Webinar Level
Intermediate to Advanced
Duration
Number of sessions: 2
Each session will be for 2 hours including 10 - 15 min for questions and answers